Clinical Trial Update: Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating QL0911 for chemotherapy-induced thrombocytopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Thrombocytopenia

Drugs mentioned

• QL0911

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Chemotherapy-induced Thrombocytopenia | Phase 2, Phase 3 | Status: COMPLETED